Disease Info Card

Peritoneal Carcinomatosis

Information about Peritoneal Carcinomatosis: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Peritoneal Carcinomatosis

Most recent studies have shown that Peritoneal Carcinomatosis shares some biological mechanisms with adenocarcinoma, carcinoma, carcinomatosis, colonic-neoplasms, colorectal-cancer, colorectal-neoplasms, liver-neoplasms, malignant-neoplasm-of-ovary, malignant-neoplasm-of-stomach, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-tumor-of-colon, mesothelioma, metastatic-malignant-neoplasm-to-the-liver, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, ovarian-neoplasm, peritoneal-neoplasms, stomach-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Peritoneal Carcinomatosis, and have been seen in publications frequently: Angiogenesis, Bioluminescence, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Killing, Cell Migration, Cell Proliferation, Coagulation, Excretion, Immune Response, Induction Of Apoptosis, Localization, Pathogenesis, Phagocytosis, Secretion, Transport, Viral Replication

Quite a number of genes have been found to play important roles in Peritoneal Carcinomatosis, such as ADA, ALB, CEACAM5, CEACAM7, CS, EGFR, EXOSC10, FN1, GNAI1, IL2, MID1, MUC16, PSG2, SECTM1, SERPINA5, SLC25A5, TNF, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.